Australia's MedAdvisor eyes best day in 10-mnths on strategic options evaluation
** Shares of MedAdvisor MDR.AX rise 18% to A$0.295, on
track for its best session since Jan. 8, if current trends hold
** Stock hit its highest level since Oct. 31
** Medical software co initiates formal review process to
evaluate strategic options to maximize shareholder value
** Stock has risen 16.3% YTD, as of last close
(Reporting by Sherin Sunny in Bengaluru)
((Sherin.Sunny@thomsonreuters.com))
Recent news on Adheris Health
See all newsBrief: Adheris Health Says Board And Management Buy 27 Million Shares
Brief: Adheris Health Appoints Alison Hale As CFO
Brief: Adheris Health Loss For Year Attributable A$4.3 Million
Brief: Adheris Health Posts Q3 Operating Revenue Of A$5.4M
Brief: Adheris Health Posts HY Profit From Ordinary Activities After Tax Attributable A$7.3 Million